Drug name
Last update: Sep 2026GS-1614
Developer(s)
Drug information
Not provided
GS-1614 (islatravir prodrug)
Not applicable (investigational; no brand name assigned)
Small molecule
Nucleoside reverse transcriptase translocation inhibitor (NRTTI) prodrug
GS-1614 is a prodrug of islatravir developed by Calibr-Skaggs (Scripps Research) and licensed to Gilead in January 2024, when Gilead exercised its option in connection with its Merck collaboration. It was being evaluated as a long-acting injectable partner for lenacapavir, with potential for quarterly dosing, in a phase 1b study in people with HIV alongside the integrase inhibitor GS-6212. Gilead discontinued the quarterly regimen with GS-1614 after evaluating the phase 1 data, as stated in its fourth-quarter 2025 prepared remarks of 10 February 2026, prioritising GS-3242 as the twice-yearly partner for lenacapavir.
Development discontinued (Gilead Q4 2025 update, 10 February 2026).
Not approved.
Therapeutic area(s)
- HIV
- Treatment
Administration route
Subcutaneous, Intramuscular
Associated long-acting platforms
Prodrug (long-acting injectable)
Use of drug
- To be determined
- Every 3 months
Product development was discontinued by the company
Dosage
Not provided
Not provided
Every 3 months injection (IM or SC) was the development target
Not provided
Not provided
Associated compounds, formulations and regimens
Not provided
Associated technologies
Not provided
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Not applicable (discontinued).
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
No delivery device
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL